3378 Stock Chart & Stats
HK$28.50
-HK$0.50(-1.72%)
―
--
Day’s Range― - ―
52-Week RangeHK$13.48 - HK$32.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.90M
Market Cap
HK$3.89B
Enterprise ValueHK$12.14B
Total Cash (Recent Filing)HK$2.46B
Total Debt (Recent Filing)HK$7.54B
Price to Earnings (P/E)87.7
Beta0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding136,218,830
10 Day Avg. Volume9,903,100
30 Day Avg. Volume9,903,100
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H News
3378 FAQ
What was Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s price range in the past 12 months?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H lowest stock price was HK$13.48 and its highest was HK$32.94 in the past 12 months.
What is Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s market cap?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s market cap is HK$3.89B.
When is Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H overvalued?
According to Wall Street analysts Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s price is currently Undervalued.
Does Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H pay dividends?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H pays a N/A dividend of HK$0.025 which represents an annual dividend yield of N/A. See more information on Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H dividends here
What is Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s EPS estimate?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H have?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has 136,218,830 shares outstanding.
What happened to Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3378
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.